Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $11.38

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given a consensus rating of “Buy” by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $13.38.

CMPX has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday. HC Wainwright boosted their target price on shares of Compass Therapeutics from $10.00 to $24.00 and gave the company a “buy” rating in a report on Friday. Finally, Piper Sandler initiated coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock.

Compass Therapeutics Stock Down 9.0 %

Shares of CMPX stock opened at $1.46 on Wednesday. The firm has a market cap of $201.89 million, a P/E ratio of -3.95 and a beta of 1.19. The company has a 50 day moving average of $2.76 and a 200-day moving average of $2.10. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, equities analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CMPX. Tower Research Capital LLC TRC grew its position in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics during the 4th quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics during the fourth quarter worth about $27,000. Intech Investment Management LLC bought a new position in shares of Compass Therapeutics in the third quarter worth approximately $30,000. Finally, Mariner LLC bought a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $30,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.